Skip to main content
Be The Investor
BTI Market Newsearnings
Back to News

Amgen's Growth Portfolio Must Outrun Biosimilar Pressure

Amgen's Growth Portfolio Must Outrun Biosimilar Pressure

Amgen raised its 2026 outlook as newer medicines grew rapidly, but falling Prolia and Xgeva sales show how quickly mature franchises can lose ground. over time.

Amgen's latest outlook shows a company growing through a portfolio transition rather than relying on one blockbuster.

The biotechnology group raised 2026 revenue guidance to $38.2 billion to $39.4 billion, for a midpoint of $38.8 billion. That is about 5% above 2025 revenue of $36.8 billion and higher than the company's previous range. Adjusted earnings guidance also increased to $22.30 to $23.50 per share.

Six growth medicines expanded by a combined 26% in the latest quarter and represented nearly 70% of product sales in Trefis's analysis. Repatha, a cholesterol treatment, grew 37%. That breadth is important because it reduces dependence on any single product and gives Amgen several routes to support revenue.

Loading market context

The decline side of the portfolio is equally clear. Combined Prolia and Xgeva sales fell 33% as biosimilar competition intensified. These medicines once formed a large, profitable franchise, so their erosion can pressure gross margin and selling efficiency even when newer drugs grow quickly.

Relative profitability remains a strength. Trefis compares Amgen's operating margin of about 30% with Johnson & Johnson's 26.8%, while recent quarterly revenue growth was 9.1% versus 8.1%. Amgen also traded near 25.8 times earnings, below the 30.2 multiple cited for Johnson & Johnson. These point-in-time multiples should not be treated as permanent, and differences in business mix limit a simple peer comparison.

The next stage depends on operating expense discipline and pipeline productivity. Growth drugs must cover not only lost mature-product revenue but also the research, launch and manufacturing costs needed to sustain the transition. Acquisitions add opportunity but also integration and development risk.

Amgen's raised guidance suggests the transition is working today. The most useful evidence in coming quarters will be volume growth for the six key medicines, the pace of biosimilar erosion and whether operating margin holds as the sales mix changes. A diversified growth portfolio can support a higher valuation, but only if its gains consistently exceed the decline of older products.

Continue your JNJ research

Find us onGoogle News

Latest comments

BT
Community Guidelines

Related News

etfs20 / 10 / 2026

Replacing a $140,000 Salary With Dividends Starts With the Yield

A $140,000 dividend target requires $3.5 million at a 4% yield, $2 million at 7% or $1.4 million at 10%. The lower capital targets bring greater payout, inflation and principal risk.

earnings20 / 10 / 2026

HPE's Growth Surge Comes With a Durability Question

HPE's reported networking and server growth reflects AI demand and the Juniper acquisition, but investors must separate acquisition-driven gains from organic growth and watch whether margins hold after the buildout slows.

earnings20 / 10 / 2026

Vertiv’s October 28 Report Must Turn AI Demand Into Margin Proof

Vertiv’s valuation has compressed while earnings estimates rose. Its next report must show that factory productivity, orders and pricing can lift margins without weakening the AI infrastructure growth story.

earnings20 / 10 / 2026

Bloom Energy’s Q3 Must Defend a Premium Valuation

Bloom Energy enters earnings with reported revenue growth expectations above 100% and a large backlog, but its earnings multiples far exceed industrial peers. Execution and cash conversion must justify the premium.

earnings20 / 10 / 2026

Coca-Cola's Growth Is Strong, but Affordability Spending Tests the Valuation

Coca-Cola's second quarter delivered 5% volume growth, 6% organic revenue growth and a higher margin. Management still sees pressure on lower-income consumers, making price mix and Asia-Pacific profitability important tests for an expensive stock.

earnings20 / 10 / 2026

PepsiCo's Q3 Results Answered the Preview: Growth Improved, Margins Stayed Tight

PepsiCo's October 8 results showed 5.6% revenue growth and faster organic growth, but North American margin pressure persisted. International businesses provided the strongest counterweight as the company moderated its earnings outlook.

Next Article
earnings 20 / 10 / 2026 Be The Investor Research 1 min read

GM Beats Q3 Estimates, Adds a $20 Billion Buyback but Narrows the Range

Share
GM Beats Q3 Estimates, Adds a $20 Billion Buyback but Narrows the Range

General Motors beat third-quarter revenue and adjusted EPS estimates, lifted its automotive cash-flow outlook and announced a $20 billion buyback. A tighter earnings range still leaves tariffs, China and EV execution as the central risks.

General Motors paired a third-quarter earnings beat with a larger cash-return promise, but the update did not remove the pressures facing its core auto business.

CNBC reported adjusted earnings of $3.70 a share, ahead of the $3.63 LSEG estimate, on revenue of $50.02 billion versus $48.7 billion expected. GM narrowed full-year adjusted EBIT guidance to $14.5 billion to $15.5 billion from $14 billion to $16 billion. It also raised the lower end of adjusted automotive free cash flow guidance to $11.5 billion, leaving a new range of $11.5 billion to $12.5 billion.

The narrower outlook is useful because it reduces the distance between the bull and bear cases. The midpoint of adjusted EBIT guidance is still $15 billion, unchanged from the prior range. The more meaningful change is cash generation: the new midpoint is $12 billion, up from $10.5 billion previously. That $1.5 billion midpoint increase gives GM more room to fund investment and repurchase shares.

GM also authorized a new multiyear $20 billion buyback after completing the $6 billion program announced in January. The company did not provide a completion date, so the authorization should not be treated as an immediate purchase. Its value to shareholders will depend on the price paid, future cash generation and whether capital needs rise.

The operating risks remain concrete. Tariffs can raise vehicle and component costs, China remains a difficult market, and electric-vehicle investment must produce returns rather than simply absorb cash. A premarket share decline of about 5% despite the beat suggests investors were weighing those risks and the guidance range against the headline results.

For investors, the quarter strengthened the cash-flow case more than the growth case. The next test is whether GM can hold the raised cash outlook while absorbing trade costs and maintaining pricing in North America.

Find us onGoogle News

Latest comments

BT
Community Guidelines
Next Article
earnings 20 / 10 / 2026 Be The Investor Research 2 min read

PepsiCo's Revenue Beat Came With a More Complicated Profit Outlook

Share
PepsiCo's Revenue Beat Came With a More Complicated Profit Outlook

PepsiCo exceeded third-quarter sales and core earnings expectations, helped by international growth and better volumes. A higher revenue outlook, however, came with softer core profit growth as costs and mix weighed on margins.

PepsiCo's third quarter showed that demand improved faster than profitability. Revenue reached $25.3 billion, above the $24.9 billion consensus cited in the original report, while core earnings of $2.34 a share topped the $2.29 estimate. The stronger top line did not translate into an equally strong profit outlook.

Reported revenue grew 5.6%. Global beverage volume rose 3% and food volume increased 1%, giving the quarter a healthier mix of price and unit growth than investors had seen during the earlier inflation-driven period. International organic revenue grew 8%, making overseas markets an important counterweight to the slower and more promotional North American consumer environment.

Management lifted its full-year reported net revenue growth expectation to about 6%. That forecast includes roughly 1.5 percentage points from currency and another 1.5 points from acquisitions, while organic revenue growth remained near 3%. The distinction matters because currency and acquired sales can raise reported growth without proving that the existing portfolio is gaining the same amount of underlying momentum.

The profit guidance moved the other way. PepsiCo projected core constant-currency earnings growth of about 2.5% to 3.5%, below the pace implied earlier in the year. The original report tied the pressure to input costs, investment and business mix. In practical terms, more sales are flowing through a cost structure that is not yet converting them into proportionate earnings growth.

That leaves investors with a two-part test. First, the volume recovery must persist after promotional activity and price changes are stripped out. Second, productivity and mix must stabilize margins so that revenue growth produces faster earnings growth. International strength is encouraging, but it cannot fully answer questions about North American snacks and beverages.

The quarter reduced concern about demand while increasing the importance of execution. PepsiCo does not need spectacular unit growth to support its defensive profile, but it does need a clearer path from mid-single-digit reported revenue growth to durable per-share earnings growth. The next report should show whether stronger volumes are becoming a margin benefit or merely offsetting higher costs.

Find us onGoogle News

Latest comments

BT
Community Guidelines
Next Article
earnings 20 / 10 / 2026 Be The Investor Research 1 min read

Mastercard’s Record Run Raises the Bar for October Earnings

Share
Mastercard’s Record Run Raises the Bar for October Earnings

Mastercard enters its October 29 report after strong second-quarter growth, leaving investors focused on cross-border volume, service revenue and whether margins can absorb continued investment.

Mastercard approaches its October 29 earnings report after a strong operating quarter and an extended share-price advance. The setup is demanding because investors are not only paying for transaction growth. They are also expecting security, authentication and other services to keep expanding faster than the core network.

In the second quarter of 2026, Mastercard reported net revenue of $9.3 billion, up 14% as reported and 12% on a currency-neutral basis. Gross dollar volume rose 8% in local currency, cross-border volume increased 12%, and switched transactions grew 9%.

Services carry the higher expectation

Payment-network revenue rose 10% as reported and 8% on a currency-neutral basis. Value-added services and solutions grew 20%, or 18% currency-neutral, driven by security, digital authentication, consumer engagement and business insights. That difference matters because services broaden Mastercard's revenue beyond the fee earned for routing a payment.

The company also reported a 60.2% GAAP operating margin, up 1.5 percentage points from a year earlier. Revenue grew faster than operating expenses in the quarter, showing operating leverage even as Mastercard continued to invest. A high valuation, however, requires that pattern to persist.

Cross-border spending is especially important because international transactions generally carry attractive economics. It is also cyclical and exposed to travel, currency and consumer confidence. A slowdown there could be partly offset by services, but investors should not assume the two businesses move independently.

The October report should be judged on a matched set of metrics: cross-border volume, switched transactions, value-added-services growth, rebates and incentives, and operating margin. Rebates rose 22% in the second quarter, faster than network revenue, reflecting the cost of winning and renewing customer relationships.

A record share price can coexist with a sound business and limited short-term upside. Mastercard's task is to show that services and payment volume can still outgrow the incentives and expenses needed to support them. Guidance for the holiday quarter will matter as much as the backward-looking earnings beat or miss.

Find us onGoogle News

Latest comments

BT
Community Guidelines
Next Article
earnings 20 / 10 / 2026 Be The Investor Research 2 min read

FMC’s Guidance Collapse Signals a Channel Reset, Not a Normal Miss

Share
FMC’s Guidance Collapse Signals a Channel Reset, Not a Normal Miss

FMC cut third-quarter revenue expectations to $65 million to $125 million and forecast a steep adjusted EBITDA loss as it discounts inventory and changes U.S. pricing.

FMC's October 15 update was not a routine guidance reduction. The crop-protection company now expects third-quarter revenue of just $65 million to $125 million and an adjusted EBITDA loss of $510 million to $565 million.

The revision includes roughly $625 million to $675 million of charges tied to commercial actions. FMC said it is lowering prices on selected products held by channel customers and changing its U.S. selling and pricing model. That means part of the loss reflects a deliberate effort to clear expensive inventory and reset relationships with distributors, not only weak end-market demand.

Why the reset is so severe

Loading market context

Agricultural-chemical companies sell through distributors, so reported sales can run ahead of product consumption on farms. If distributors hold inventory purchased at old prices while demand weakens, new shipments slow and price protection or rebates can become necessary. FMC's update suggests that gap became large enough to require an abrupt correction.

The company had previously expected third-quarter revenue of $840 million to $900 million excluding India and adjusted EBITDA of $120 million to $140 million. The new range therefore represents a break in the operating model, not a modest forecast error. Investors must now evaluate how much inventory remains, whether the new pricing restores sell-through and how much cash the program consumes.

Balance-sheet flexibility matters because FMC has also been negotiating with lenders. An April 2026 credit amendment waived the maximum leverage test for the March quarter and changed future covenant terms. Covenant relief can provide time, but it does not erase debt or turn an EBITDA loss into cash.

Corteva is a useful peer, not a direct substitute. Its product mix, balance sheet and channel exposure differ, so FMC's warning should not be mechanically applied to every agricultural input company. The event does, however, show how quickly distributor inventory can reverse apparent pricing power.

The next earnings release needs to reconcile the commercial charges, cash effects and revised inventory position. Until FMC demonstrates normalized orders and positive cash generation, the stock's lower price alone is not evidence that the reset is complete.

Find us onGoogle News

Latest comments

BT
Community Guidelines